Wire · opportunities
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA approved obinutuzumab (Gazyva) for treatment of idiopathic nephrotic syndrome (INS) in patients aged 2 years and older, marking the first FDA-approved treatment for INS in 70 years. The approval is based on phase 3 INShore trial results showing 95% remission at 52 weeks compared to 73% for standard treatment with mycophenolate mofetil (MMF).
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 25 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
You can now access the first new FDA-approved treatment for idiopathic nephrotic syndrome in decades, opening a chance to replace steroids with a more effective alternative. This approval rewrites care standards for childhood kidney disease and reallocates patient risk profiles away from steroids.
◆ Coverage
3 sources · first reported 25 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics